Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Neurocrine Biosciences (NASDAQ: NBIX) has scheduled its second quarter 2025 financial results conference call and webcast for July 30, 2025, at 1:30 p.m. Pacific Time. The company will release its Q2 2025 financial results at 1:00 p.m. PT on the same day.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for multiple conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a diverse pipeline with several compounds in mid to late-phase clinical development.
Neurocrine Biosciences (NASDAQ: NBIX) ha programmato la conference call e la trasmissione web dei risultati finanziari del secondo trimestre 2025 per il 30 luglio 2025 alle 13:30 ora del Pacifico. L'azienda pubblicherà i risultati finanziari del Q2 2025 alle 13:00 PT dello stesso giorno.
Neurocrine Biosciences è una società biofarmaceutica specializzata in neuroscienze con trattamenti approvati dalla FDA per diverse patologie, tra cui discinesia tardiva, corea di Huntington, iperplasia surrenalica congenita, endometriosi e fibromi uterini. L'azienda dispone di un ampio portafoglio di prodotti con diversi composti in fase clinica medio-avanzata.
Neurocrine Biosciences (NASDAQ: NBIX) ha programado su llamada y webcast para presentar los resultados financieros del segundo trimestre de 2025 el 30 de julio de 2025 a la 1:30 p.m. hora del Pacífico. La compañía publicará sus resultados financieros del Q2 2025 a la 1:00 p.m. PT el mismo día.
Neurocrine Biosciences es una empresa biofarmacéutica enfocada en neurociencias con tratamientos aprobados por la FDA para múltiples condiciones, incluyendo discinesia tardía, corea de Huntington, hiperplasia suprarrenal congénita, endometriosis y fibromas uterinos. La compañía mantiene una cartera diversa con varios compuestos en desarrollo clínico de fase media a avanzada.
Neurocrine Biosciences (NASDAQ: NBIX)는 2025년 7월 30일 태평양 표준시 오후 1시 30분에 2025년 2분기 재무 실적 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 회사는 같은 날 오후 1시(PT)에 2분기 2025년 재무 실적을 발표할 예정입니다.
Neurocrine Biosciences는 지연성 운동장애, 헌팅턴 무도병, 선천성 부신과형성증, 자궁내막증, 자궁근종 등 여러 질환에 대해 FDA 승인 치료제를 보유한 신경과학 중심의 바이오제약 회사입니다. 회사는 중기에서 후기 임상 개발 단계에 있는 여러 화합물을 포함한 다양한 파이프라인을 보유하고 있습니다.
Neurocrine Biosciences (NASDAQ : NBIX) a programmé sa conférence téléphonique et son webcast concernant les résultats financiers du deuxième trimestre 2025 pour le 30 juillet 2025 à 13h30, heure du Pacifique. La société publiera ses résultats financiers du T2 2025 à 13h00 PT le même jour.
Neurocrine Biosciences est une société biopharmaceutique spécialisée en neurosciences, disposant de traitements approuvés par la FDA pour plusieurs affections, notamment la dyskinésie tardive, la chorée de Huntington, l'hyperplasie congénitale des surrénales, l'endométriose et les fibromes utérins. La société possède un portefeuille diversifié avec plusieurs composés en développement clinique de phase intermédiaire à avancée.
Neurocrine Biosciences (NASDAQ: NBIX) hat seine Telefonkonferenz und Webcast zur Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 30. Juli 2025 um 13:30 Uhr Pazifikzeit angesetzt. Das Unternehmen wird seine Finanzergebnisse für Q2 2025 am selben Tag um 13:00 Uhr PT veröffentlichen.
Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften und verfügt über FDA-zugelassene Behandlungen für mehrere Erkrankungen, darunter tardive Dyskinesie, Chorea Huntington, kongenitale adrenale Hyperplasie, Endometriose und Uterusmyome. Das Unternehmen verfügt über eine vielfältige Pipeline mit mehreren Wirkstoffen in mittleren bis späten klinischen Entwicklungsphasen.
- None.
- None.
Conference Call and Webcast Scheduled for Wednesday, July 30
The schedule for the press release and conference call / webcast is as follows:
- Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
- Q2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-225-9448
- International Dial-In Number: 203-518-9708
- Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2025-financial-results-302501556.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) Q2 2025 earnings call?
How can I access Neurocrine Biosciences Q2 2025 earnings call?
What treatments does Neurocrine Biosciences (NBIX) have FDA approval for?
How long will Neurocrine's Q2 2025 earnings webcast be available?
